Senta Frol1, Janja Pretnar Oblak1. 1. Department of Vascular Neurology and Intensive Neurological Therapy, University Medical Center Ljubljana, Ljubljana, Slovenia.
Abstract
BACKGROUND: Intracranial hemorrhage (ICH) is a serious, life-threatening, but fortunately rare complication of non-vitamin K oral anticoagulant (NOAC) therapy. There are limited data on NOAC-related ICH prognosis. METHODS: All consecutive patients admitted to a single center due to acute NOAC-related ICH from September 2012 until the beginning of 2017 were included. Risk factors, type of NOAC, and location of ICH were evaluated. Risk for ischemic and bleeding events and clinical status upon admission and at discharge were evaluated using standard scales. RESULTS: Thirty-four patients aged 77.8 ± 8.3 years with NOAC-related ICH were included. The main predisposing risk factors were age and arterial hypertension. The median CHA2DS2-VASc score was 3.4 and the median HAS-BLED score was 1.8. Eighteen patients were treated with rivaroxaban, 11 with dabigatran, and 5 with apixaban. Ten patients (29%) had a favorable outcome with a modified Rankin Scale score ≤2 and 13 patients (38%) died. The location of the ICH was mainly intraparenchymal and subdural. CONCLUSIONS: Our retrospective single-center study shows that the mortality rate with NOAC-related ICH is <40%, which makes it comparable to that with vitamin K antagonist-related ICH.
BACKGROUND: Intracranial hemorrhage (ICH) is a serious, life-threatening, but fortunately rare complication of non-vitamin K oral anticoagulant (NOAC) therapy. There are limited data on NOAC-related ICH prognosis. METHODS: All consecutive patients admitted to a single center due to acute NOAC-related ICH from September 2012 until the beginning of 2017 were included. Risk factors, type of NOAC, and location of ICH were evaluated. Risk for ischemic and bleeding events and clinical status upon admission and at discharge were evaluated using standard scales. RESULTS: Thirty-four patients aged 77.8 ± 8.3 years with NOAC-related ICH were included. The main predisposing risk factors were age and arterial hypertension. The median CHA2DS2-VASc score was 3.4 and the median HAS-BLED score was 1.8. Eighteen patients were treated with rivaroxaban, 11 with dabigatran, and 5 with apixaban. Ten patients (29%) had a favorable outcome with a modified Rankin Scale score ≤2 and 13 patients (38%) died. The location of the ICH was mainly intraparenchymal and subdural. CONCLUSIONS: Our retrospective single-center study shows that the mortality rate with NOAC-related ICH is <40%, which makes it comparable to that with vitamin K antagonist-related ICH.
Entities:
Keywords:
Intracranial hemorrhage; Non-vitamin K oral anticoagulant therapy; Prognosis
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: Jan C Purrucker; Kirsten Haas; Timolaos Rizos; Shujah Khan; Marcel Wolf; Michael G Hennerici; Sven Poli; Christoph Kleinschnitz; Thorsten Steiner; Peter U Heuschmann; Roland Veltkamp Journal: JAMA Neurol Date: 2016-02 Impact factor: 18.302
Authors: Duncan Wilson; David J Seiffge; Christopher Traenka; Ghazala Basir; Jan C Purrucker; Timolaos Rizos; Oluwaseun A Sobowale; Hanne Sallinen; Shin-Joe Yeh; Teddy Y Wu; Marc Ferrigno; Rik Houben; Floris H B M Schreuder; Luke A Perry; Jun Tanaka; Marion Boulanger; Rustam Al-Shahi Salman; Hans R Jäger; Gareth Ambler; Clare Shakeshaft; Yusuke Yakushiji; Philip M C Choi; Julie Staals; Charlotte Cordonnier; Jiann-Shing Jeng; Roland Veltkamp; Dar Dowlatshahi; Stefan T Engelter; Adrian R Parry-Jones; Atte Meretoja; David J Werring Journal: Neurology Date: 2017-04-05 Impact factor: 9.910